ArticleRisk management and healthcare policy2026
Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective.
Xiaoyu Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.